Matrix metalloproteinases: Multifunctional contributors to tumor progression

Molecular Medicine Today

Volumn 6, Issue 4, 2000, Pages 149-156

  McCawley, Lisa J ^a   Matrisian, Lynn M ^a  

^a VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

MARIMASTAT; MATRIX METALLOPROTEINASE; MATRIX METALLOPROTEINASE INHIBITOR; TANOMASTAT;

ADVANCED CANCER; ANGIOGENESIS; CANCER GROWTH; CANCER INVASION; EXTRACELLULAR MATRIX; HUMAN; LUNG SMALL CELL CANCER; METASTASIS; NONHUMAN; PANCREAS CARCINOMA; PROTEIN DOMAIN; PROTEIN EXPRESSION; PROTEIN FAMILY; REVIEW; STOMACH CARCINOMA; STROMA;

ANIMALS; BASEMENT MEMBRANE; DISEASE PROGRESSION; ENZYME INHIBITORS; EXTRACELLULAR MATRIX; HUMANS; MATRIX METALLOPROTEINASES; NEOPLASM INVASIVENESS; NEOPLASM METASTASIS; NEOPLASM PROTEINS; NEOPLASM STAGING; NEOPLASMS; NEOVASCULARIZATION, PATHOLOGIC;

ANIMALIA;

EID: 0034176764     PISSN: 13574310     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1357-4310(00)01686-5     Document Type: Review

References (54)

1. Lukashev M.E., Werb Z. ECM signalling: orchestrating cell behaviour and misbehaviour. Trends Cell Biol. 8:1998;437-441.
2. Nagase H., Woessner J.F. Jr. Matrix metalloproteinases. J. Biol. Chem. 274:1999;21491-21494.
3. Fidler I.J. Molecular biology of cancer: invasion and metastasis. Devita V.T.et al. Cancer: Principles and Practice of Oncology (5th edn). 1997;135-152 Lippincott-Raven.
4. Schwarzbauer J. Basement membranes: Putting up the barriers. Curr. Biol. 9:1999;R242-R244.
5. Stetler-Stevenson W.G.et al. Matrix metalloproteinases and tumor invasion - from correlation and causality to the clinic. Semin. Cancer Biol. 7:1996;147-154.
6. Massova I.et al. Matrix metalloproteinases: structures, evolution, and diversification. FASEB J. 12:1998;1075-1095.
7. Lovejoy B.et al. Structure of the catalytic domain of fibroblast collagenase complexed with an inhibitor. Science. 263:1994;375-377.
8. Sanchez-Lopez R.et al. Role of zinc-binding- and hemopexin domain-encoded sequences in the substrate specificity of collagenase and stromelysin-2 as revealed by chimeric proteins. J. Biol. Chem. 268:1993;7238-7247.
9. Baragi V.M.et al. Contribution of the C-terminal domain of metalloproteinases to binding by tissue inhibitor of metalloproteinases. C-terminal truncated stromelysin and matrilysin exhibit equally compromised binding affinities as compared to full-length stromelysin. J. Biol. Chem. 269:1994;12692-12697.
10. Ward R.V.et al. Cell surface-mediated activation of progelatinase A: Demonstration of the involvement of the C-terminal domain of progelatinase A in cell surface binding and activation of progelatinase A by primary fibroblasts. Biochem. J. 304:1994;263-269.
11. Murphy G.et al. Assessment of the role of the fibronectin-like domain of gelatinase A by analysis of a deletion mutant. J. Biol. Chem. 269:1994;6632-6636.
12. Sato H.et al. A matrix metalloproteinase expressed on the surface of invasive tumour cells. Nature. 370:1994;61-64.
13. Edwards D.R.et al. The roles of tissue inhibitors of metalloproteinases in tissue remodelling and cell growth. Int. J. Obes. 20:1996;S9-S15.
14. Gomez D.E.et al. Tissue inhibitors of metalloproteinases: structure, regulation and biological function. Eur. J. Cell Biol. 74:1997;111-122.
15. Brown P.D. Matrix metalloproteinase inhibitors. Angiogenesis. 1:1997;142-154.
16. Gross J., Lapiere C.M. Collagenolytic activity in amphibian tissues: a tissue culture assay. Proc. Natl. Acad. Sci. U. S. A. 48:1962;1014-1022.
17. Hulboy D.L.et al. Matrix metalloproteinases as mediators of reproductive function. Mol. Hum. Reprod. 3:1997;27-45.
18. Jones L.et al. The matrix metalloproteinases and their inhibitors in the treatment of pancreatic cancer. Ann. New York Acad. Sci. 880:1999;288-307.
19. Drummond A.H.et al. Preclinical and clinical studies of MMP inhibitors in cancer. Ann. New York Acad. Sci. 878:1999;228-235.
20. Shalinsky D.R.et al. Broad antitumor and antiangiogenic activities of AG3340, a potent and selective MMP inhibitor undergoing advanced oncology clinical trials. Ann. New York Acad. Sci. 878:1999;236-270.
21. Matrisian L.M.et al. Isolation of the oncogene and epidermal growth factor-induced transin gene: complex control in rat fibroblasts. Mol. Cell. Biol. 6:1986;1679-1686.
22. Crawford H.C., Matrisian L.M. Mechanisms controlling the transcription of matrix metalloproteinase genes in normal and neoplastic cells. Enzyme Protein. 49:1996;20-37.
23. Liotta L.A.et al. Metastatic potential correlates with enzymatic degradation of basement membrane collagen. Nature. 284:1980;67-68.
24. Nakajima M.et al. Degradation of basement membrane type IV collagen and lung subendothelial matrix by rat mammary adenocarcinoma cell clones of differing metastatic potentials. Cancer Res. 47:1987;4869-4876.
25. Lochter A.et al. Matrix metalloproteinase stromelysin-1 triggers a cascade of molecular alterations that leads to stable epithelial-to-mesenchymal conversion and a premalignant phenotype in mammary epithelial cells. J. Cell Biol. 139:1997;1861-1872.
26. Sternlicht M.D.et al. The stromal proteinase MMP3/stromelysin-1 promotes mammary carcinogenesis. Cell. 98:1999;137-146.
27. Murphy A.N.et al. Tissue inhibitor of metalloproteinases-2 inhibits bFGF-induced human microvascular endothelial cell proliferation. J. Cell. Physiol. 157:1993;351-358.
28. Alvarez O.A.et al. Inhibition of collagenolytic activity and metastasis of tumor cells by a recombinant human tissue inhibitor of metalloproteinases, J. Natl. Cancer Inst. 82:1990;589-595.
29. Khokha R. Suppression of the tumorigenic and metastatic abilities of murine B16-F10 melanoma cells in vivo by the overexpression of the tissue inhibitor of the metalloproteinases-1. J. Natl. Cancer Inst. 86:1994;299-304.
30. Yoneda T.et al. Inhibition of osteolytic bone metastasis of breast cancer by combined treatment with the bisphosphonate ibandronate and tissue inhibitor of the matrix metalloproteinase-2. J. Clin. Invest. 99:1997;2509-2517.
31. Chambers A.F., Matrisian L.M. Changing views of the role of matrix metalloproteinases in metastasis. J. Natl. Cancer Inst. 89:1997;1260-1270.
32. Koop S.et al. Overexpression of metalloproteinase inhibitor in B16F10 cells does not affect extravasation but reduces tumor growth. Cancer Res. 54:1994;4791-4797.
33. Wylie S.et al. The matrix metalloproteinase inhibitor batimastat inhibits angiogenesis in liver metastasis of B16F1 melanoma cells. Clin. Exp. Metastasis. 17:1998;111-117.
34. Xia T.et al. Comparison of cleavage site specificity of gelatinases A and B using collagenous peptides. Biochim. Biophys. Acta. 1293:1996;259-266.
35. Biswas C.et al. The human tumor cell-derived collagenase stimulatory factor (renamed EMMPRIN) is a member of the immunoglobulin superfamily. Cancer Res. 55:1995;434-439.
36. Rudolph-Owen L.A.et al. The matrix metalloproteinase matrilysin influences early-stage mammary tumorigenesis. Cancer Res. 58:1998;5500-5506.
37. D'Armiento J.et al. Collagenase expression in transgenic mouse skin causes hyperkeratosis and acanthosis and increases susceptibility to tumorigenesis. Mol. Cell. Biol. 15:1995;5732-5739.
38. Wilson C.L.et al. Intestinal tumorigenesis is suppressed in mice lacking the metalloproteinase matrilysin. Proc. Natl. Acad. Sci. U. S. A. 94:1997;1402-1407.
39. Masson R.et al. In vivo evidence that the stromelysin-3 metalloproteinase contributes in a paracrine manner to epithelial cell malignancy. J. Cell Biol. 140:1998;1535-1541.
40. Stetler-Stevenson W.G. Matrix metalloproteinases in angiogenesis: a moving target for therapeutic intervention. J. Clin. Invest. 103:1999;1237-1241.
41. Brooks P.C.et al. Disruption of angiogenesis by PEX, a noncatalytic metalloproteinase fragment with integrin binding activity. Cell. 92:1998;391-400.
42. Itoh T.et al. Reduced angiogenesis and tumor progression in gelatinase A-deficient mice. Cancer Res. 58:1998;1048-1051.
43. Giancotti F.G., Ruoslahti E. Integrin signaling. Science. 285:1999;1028-1032.
44. 3 rescues melanoma cells from apoptosis in a three-dimensional dermal collagen. Proc. Natl. Acad. Sci. U. S. A. 91:1994;8856-8860.
45. Giannelli G.et al. Induction of cell migration by matrix metalloprotease-2 cleavage of laminin-5. Science. 277:1997;225-228.
46. Imai K.et al. Degradation of decorin by matrix metalloproteinases: identification of the cleavage sites, kinetic analyses and transforming growth factor-beta1 release. Biochem. J. 322:1997;809-814.
47. Ugwu F.et al. Proteolytic cleavage of urokinase-type plasminogen activator by stromelysin-1 (MMP-3). Biochemistry. 37:1998;7231-7236.
48. von Bredow D.C.et al. Cleavage of beta 4 integrin by matrilysin. Exp. Cell Res. 236:1997;341-345.
49. Birchmeier W. E-cadherin as a tumor (invasion) suppressor gene. BioEssays. 17:1995;97-99.
50. Suzuki M.et al. Matrix metalloproteinase-3 releases active heparin-binding EGF-like growth factor by cleavage at a specific juxtamembrane site. J. Biol. Chem. 272:1997;31730-31737.
51. Levi E.et al. Matrix metalloproteinase 2 releases active soluble ectodomain of fibroblast growth factor receptor 1. Proc. Natl. Acad. Sci. U. S. A. 93:1996;7069-7074.
52. Schonbeck U.et al. Generation of biologically active IL-1 beta by matrix metalloproteinases: a novel caspase-1-independent pathway of IL-1 beta processing. J. Immunol. 161:1998;3340-3346.
53. Fowlkes J.L.et al. Matrix metalloproteinases degrade insulin-like growth factor-binding protein-3 in dermal fibroblast cultures. J. Biol. Chem. 269:1994;25742-25746.
54. Bergers G.et al. Effects of angiogenesis inhibitors on multistage carcinogenesis in mice. Science. 284:1999;808-812.